A phase 2 expansion study of ARV-766, a PROTACĀ® androgen receptor degrader, in metastatic castration-resistant prostate cancer - Plain Language Summary

Daniel P Petrylak, et al.

February 16, 2023
ASCO Genitourinary Cancers Symposium


You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content